Among the most commonly reported side effects of anti-IL-23 therapy are infections (the most common of which are upper respiratory tract viral infections, the incidence of severe infections being below 1.5%), the risk of developing malignancies, headache, arthralgia, myalgia, injection site reactions (erythema), odynophagia, cough, diarrhea, nausea, vomiting, fever, chills, anaphylactic reactions, pruritus, increased liver enzymes (7.43% of patients), cardiovascular events, hypertension arterial, purpura, paradoxical reaction (worsening of the underlying pathology), and depression [60]. This evidence concerns the gene IL37 and depressive symptom measurement.